Lamotrigine-Induced Blood Dyscrasias in Association with Rash
DOI:
https://doi.org/10.4212/cjhp.v60i4.187Abstract
INTRODUCTION
Lamotrigine is used to treat a number of disease states, including bipolar disorder. It is generally well tolerated, with dizziness, insomnia, and skin rashes being the adverse effects most often reported. The prevalence of rash among patients receiving lamotrigine is approximately 10%, but serious rashes associated with hospital admission are rare (0.3%).1 Increased frequency of dermatologic events has been associated with more rapid initial titration of lamotrigine and with concomitant use of valproic acid, a known inhibitor of lamotrigine metabolism.1 Blood dyscrasias associated with lamotrigine have been reported, but the numbers are too few to estimate the incidence.1 We report here a case of lamotrigine-induced leukopenia (leukocyte count less than 4.0 x 109/L) and neutropenia (neutrophil count less than 1.5 x 109/L) associated with rash. This case illustrates the potential morbidity associated with lamotrigineinduced blood dyscrasias.
Downloads
Downloads
Issue
Section
License
Copyright © Canadian Society of Healthcare-Systems Pharmacy.
After publication of a manuscript in the CJHP, the authors of the manuscript must obtain written permission from the CSHP (publications@cshp.ca) before reproducing any text, figures, tables, or illustrations from the work in future works of their own. If a submitted manuscript is declined for publication in the CJHP, all said rights shall revert to the authors. Please note that any forms (e.g., preprinted orders and patient intake forms) used by a specific hospital or other health care facility and included as illustrative material with a manuscript are exempt from this copyright transfer. The CJHP will require a letter from the hospital or health care facility granting permission to publish the document(s).
